CDKN2A and lymphoma: FoxO inhibition in dnFoxO-expressing MYC-driven lymphomas promotes cell proliferation, while that in ARF-deficient MYC-driven lymphomas does not affect tumorigenicity, suggesting that FoxO inhibits MYC-derived lymphomagenesis by binding to the ARF promoter and inducing ARF expression.